Experimental eye injection offers hope for those losing sight to rare genetic diseases
NCT ID NCT05282953
Summary
This early-stage study is testing the safety and tolerability of an experimental drug called KIO-301, which is injected directly into the eye. It aims to help adults aged 18-80 with severe vision loss from genetic eye diseases like retinitis pigmentosa and choroideremia. The main goal is to see if the treatment is safe and well-tolerated at different dose levels.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harley Eye Clinic
COMPLETEDNorth Adelaide, South Australia, 5006, Australia
-
Royal Adelaide Hospital
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Save Sight Institute
RECRUITINGSydney, New South Wales, 2001, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.